| abstract |
Compound having the structure of formula I: or any pharmaceutically acceptable salt thereof, wherein: each of XI, X2, X3, X4 and X5 is independently No C; in which no more than two of XI, X2, X3 and N are; X8 is No C; X7, X9, X1 ° and X12 are each independently N or C; each of X8 and X1 is C; in which no more than three of X7, X9,) (10 and -12 x are N; Yes NH, NR5, CH (OH), C (> = 0), -CRaRb or CF2; or alternatively Y y1: 13 form a 5- to 6-membered ring condensed with the ring containing both said Y and 113; Z is NH, NR8, S, SO, SO2, 0 or C; where Z is only C when X5 is N; m is 10, 1 , 2, 3 6 4; n is 0, 1 6 2; p is 0, 1 6 2; RI is selected from the group consisting of (a) alk C1-2, haloalk C1-4, -0Ra, -N ( Ra) C (.0) Rb, -C (> = 0) Rd, -C (> = 0) -0-1: 18, ORc, -NRaRc, -N (R5C (> = 0) Rb, -N (Ra) C (.0) 19`, -C (> = 0) NRaRb 0 -C (.0) NRaRc; (b) a saturated, partially saturated, 3, 4, 5, 6 or 7-membered monocyclic ring unsaturated or a saturated or partially saturated 8, 9, 10, 11 6 12 membered cyclic ring, in which each of said rings contains 0, 1, 2, 3 6 4 atoms of N and 0, 1 6 2 atoms selected from 0 and S, and in which each of said rings is substituted with 0, 1, 2 6 3 groups selected from F, Cl, Br, alk C1.6, haloalk C1.4, -0-haloalk C1-4, CN, -C (> = 0) Rb, -C (> = 0) 01: 18, -C (> = 0) NRaRa, -C (> = NRa) NRaRa, -0C (.0) Rb, -0C (.0) NRalzr, -0-alk C26NRaRa, -0-alk C2.6- 0198, -SR8, -S (.> =. 0) Rb, -S (> = 0) 2Rb, -S (> = 0) 2NFPRa, -NRaRa, -NRaFle, -N (Ra) C (> = 0 ) Rb, -N (Ra) C (> = 0) 0R3, -N (Ra) C (> = 0) NR9Ra, -N (RIC (> = NRa) NRaRa, -N (Ra) S (> = 0 ) 2Rb, -N (Ra) S (> = 0) 2NRaRa, NRaalk C2.6-NRIV, -NRa-alk C2.6-0Fla, -alk C1.6-NR8In -alk -alk C1.6-N ( R8) C (> = 0) Rb, -alk C1.6-0C (> = 0) Rb, -alk C1.6-C (> = 0) NIVRa, -alk Cl_6-C (.0) 0Fta, R7 , R8 and oxo. |